167 related articles for article (PubMed ID: 30487139)
1. Antagonism of Glycolysis and Reductive Carboxylation of Glutamine Potentiates Activity of Oncolytic Adenoviruses in Cancer Cells.
Dyer A; Schoeps B; Frost S; Jakeman P; Scott EM; Freedman J; Jacobus EJ; Seymour LW
Cancer Res; 2019 Jan; 79(2):331-345. PubMed ID: 30487139
[TBL] [Abstract][Full Text] [Related]
2. Expression of human CD46 and trans-complementation by murine adenovirus 1 fails to allow productive infection by a group B oncolytic adenovirus in murine cancer cells.
Lei J; Jacobus EJ; Taverner WK; Fisher KD; Hemmi S; West K; Slater L; Lilley F; Brown A; Champion B; Duffy MR; Seymour LW
J Immunother Cancer; 2018 Jun; 6(1):55. PubMed ID: 29898782
[TBL] [Abstract][Full Text] [Related]
3. Functional interactions of antiapoptotic proteins and tumor necrosis factor in the context of a replication-competent adenovirus.
Liu TC; Wang Y; Hallden G; Brooks G; Francis J; Lemoine NR; Kirn D
Gene Ther; 2005 Sep; 12(17):1333-46. PubMed ID: 15920462
[TBL] [Abstract][Full Text] [Related]
4. Etoposide enhances antitumor efficacy of MDR1-driven oncolytic adenovirus through autoupregulation of the MDR1 promoter activity.
Su BH; Shieh GS; Tseng YL; Shiau AL; Wu CL
Oncotarget; 2015 Nov; 6(35):38308-26. PubMed ID: 26515462
[TBL] [Abstract][Full Text] [Related]
5. Viral genome DNA/lipoplexes elicit in situ oncolytic viral replication and potent antitumor efficacy via systemic delivery.
Kwon OJ; Kang E; Kim S; Yun CO
J Control Release; 2011 Oct; 155(2):317-25. PubMed ID: 21699929
[TBL] [Abstract][Full Text] [Related]
6. Assessment of the Na/I symporter as a reporter gene to visualize oncolytic adenovirus propagation in peritoneal tumours.
Merron A; Baril P; Martin-Duque P; de la Vieja A; Tran L; Briat A; Harrington KJ; McNeish IA; Vassaux G
Eur J Nucl Med Mol Imaging; 2010 Jul; 37(7):1377-85. PubMed ID: 20140612
[TBL] [Abstract][Full Text] [Related]
7. Triple-targeted oncolytic adenoviruses featuring the cox2 promoter, E1A transcomplementation, and serotype chimerism for enhanced selectivity for ovarian cancer cells.
Bauerschmitz GJ; Guse K; Kanerva A; Menzel A; Herrmann I; Desmond RA; Yamamoto M; Nettelbeck DM; Hakkarainen T; Dall P; Curiel DT; Hemminki A
Mol Ther; 2006 Aug; 14(2):164-74. PubMed ID: 16580264
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic potential of replication-selective oncolytic adenoviruses on cells from familial and sporadic desmoid tumors.
Peerlinck I; Amini-Nik S; Phillips RK; Iggo R; Lemoine NR; Tejpar S; Vassaux G
Clin Cancer Res; 2008 Oct; 14(19):6187-92. PubMed ID: 18829497
[TBL] [Abstract][Full Text] [Related]
9. A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo.
Li B; Liu X; Fan J; Qi R; Bo L; Gu J; Qian Q; Qian C; Liu X
J Gene Med; 2006 Oct; 8(10):1232-42. PubMed ID: 16900558
[TBL] [Abstract][Full Text] [Related]
10. Tumor suppressor in lung cancer-1 (TSLC1) mediated by dual-regulated oncolytic adenovirus exerts specific antitumor actions in a mouse model.
Lei W; Liu HB; Wang SB; Zhou XM; Zheng SD; Guo KN; Ma BY; Xia YL; Tan WS; Liu XY; Wang YG
Acta Pharmacol Sin; 2013 Apr; 34(4):531-40. PubMed ID: 23503473
[TBL] [Abstract][Full Text] [Related]
11. Oncolytic adenoviruses for the treatment of brain tumors.
Gomez-Manzano C; Fueyo J
Curr Opin Mol Ther; 2010 Oct; 12(5):530-7. PubMed ID: 20886384
[TBL] [Abstract][Full Text] [Related]
12. Quantitative Virus-Associated RNA Detection to Monitor Oncolytic Adenovirus Replication.
Brachtlova T; Li J; van der Meulen-Muileman IH; Sluiter F; von Meijenfeldt W; Witte I; Massaar S; van den Oever R; de Vrij J; van Beusechem VW
Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928259
[TBL] [Abstract][Full Text] [Related]
13. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis.
DeBerardinis RJ; Mancuso A; Daikhin E; Nissim I; Yudkoff M; Wehrli S; Thompson CB
Proc Natl Acad Sci U S A; 2007 Dec; 104(49):19345-50. PubMed ID: 18032601
[TBL] [Abstract][Full Text] [Related]
14. Treatment of chemotherapy resistant ovarian cancer with a MDR1 targeted oncolytic adenovirus.
Rein DT; Volkmer A; Beyer IM; Curiel DT; Janni W; Dragoi A; Hess AP; Maass N; Baldus SE; Bauerschmitz G; Breidenbach M
Gynecol Oncol; 2011 Oct; 123(1):138-46. PubMed ID: 21741695
[TBL] [Abstract][Full Text] [Related]
15. Enhanced antitumor efficacy of fiber-modified, midkine promoter-regulated oncolytic adenovirus in human malignant mesothelioma.
Takagi-Kimura M; Yamano T; Tamamoto A; Okamura N; Okamura H; Hashimoto-Tamaoki T; Tagawa M; Kasahara N; Kubo S
Cancer Sci; 2013 Nov; 104(11):1433-9. PubMed ID: 23962292
[TBL] [Abstract][Full Text] [Related]
16. Oncolytic adenoviruses for the treatment of human cancer: focus on translational and clinical data.
Pesonen S; Kangasniemi L; Hemminki A
Mol Pharm; 2011 Feb; 8(1):12-28. PubMed ID: 21126047
[TBL] [Abstract][Full Text] [Related]
17. A novel Golgi protein (GOLPH2)-regulated oncolytic adenovirus exhibits potent antitumor efficacy in hepatocellular carcinoma.
Wang Y; Liu T; Huang P; Zhao H; Zhang R; Ma B; Chen K; Huang F; Zhou X; Cui C; Liu X
Oncotarget; 2015 May; 6(15):13564-78. PubMed ID: 25980438
[TBL] [Abstract][Full Text] [Related]
18. Targeting human breast cancer cells by an oncolytic adenovirus using microRNA-targeting strategy.
Shayestehpour M; Moghim S; Salimi V; Jalilvand S; Yavarian J; Romani B; Mokhtari-Azad T
Virus Res; 2017 Aug; 240():207-214. PubMed ID: 28867494
[TBL] [Abstract][Full Text] [Related]
19. Boosting oncolytic adenovirus potency with magnetic nanoparticles and magnetic force.
Tresilwised N; Pithayanukul P; Mykhaylyk O; Holm PS; Holzmüller R; Anton M; Thalhammer S; Adigüzel D; Döblinger M; Plank C
Mol Pharm; 2010 Aug; 7(4):1069-89. PubMed ID: 20550160
[TBL] [Abstract][Full Text] [Related]
20. Oncolytic Replication of E1b-Deleted Adenoviruses.
Cheng PH; Wechman SL; McMasters KM; Zhou HS
Viruses; 2015 Nov; 7(11):5767-79. PubMed ID: 26561828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
